ABSTRACT
OBJECTIVE@#To study the effect of sitagliptin on adipocytokines expression in diabetic rats and its molecular mechanism.@*METHODS@#Male SD rats were chosen and randomly divided into NC group, T2DM group, SP group and SP + LY group. NC group received conventional breeding, T2DM group, SP group and SP + LY group received intraperitoneal injection of streptozotocin after 12 weeks of high-fat diet to establish diabetes animal model, SP group received sitagliptin intervention and SP + LY group received sitagliptin combined with PI3K inhibitor LY294002 intervention. Six weeks after the intervention, serum was collected to determine the levels of biochemical indexes and adipocytokines, and visceral adipose tissue was collected to determine expression levels of adipocytokines.@*RESULTS@#Serum TC, TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as HOMA-IR of T2DM group were higher than those of NC group, and HDL-C, Adiponectin and Omentin-1 levels were significantly lower than those of NC group; serum TC, TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as HOMA-IR of SP group were lower than those of T2DM group, and HDL-C, Adiponectin and Omentin-1 levels were significantly higher than those of T2DM group; Leptin and Chemerin levels in serum and visceral adipose tissue of SP + LY group were higher than those of SP group while Adiponectin and Omentin-1 levels were significantly lower than those of SP group.@*CONCLUSION@#Sitagliptin can regulate the expression of adipocytokines in adipose tissue of diabetic rats through PI3K-AKT pathway.
ABSTRACT
Objective To study the effect of sitagliptin on adipocytokines expression in diabetic rats and its molecular mechanism. Methods Male SD rats were chosen and randomly divided into NC group, T2DM group, SP group and SP + LY group. NC group received conventional breeding, T2DM group, SP group and SP + LY group received intraperitoneal injection of streptozotocin after 12 weeks of high-fat diet to establish diabetes animal model, SP group received sitagliptin intervention and SP + LY group received sitagliptin combined with PI3K inhibitor LY294002 intervention. Six weeks after the intervention, serum was collected to determine the levels of biochemical indexes and adipocytokines, and visceral adipose tissue was collected to determine expression levels of adipocytokines. Results Serum TC, TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as HOMA-IR of T2DM group were higher than those of NC group, and HDL-C, Adiponectin and Omentin-1 levels were significantly lower than those of NC group; serum TC, TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as HOMA-IR of SP group were lower than those of T2DM group, and HDL-C, Adiponectin and Omentin-1 levels were significantly higher than those of T2DM group; Leptin and Chemerin levels in serum and visceral adipose tissue of SP + LY group were higher than those of SP group while Adiponectin and Omentin-1 levels were significantly lower than those of SP group. Conclusion Sitagliptin can regulate the expression of adipocytokines in adipose tissue of diabetic rats through PI3K-AKT pathway.
ABSTRACT
Objective: To observe the effect of kaempferol on the correlation factors of chronic complications of type 2 diabetic rats. Methods: Feeding high-fat diet combined with ip injection of 30 mg/kg STZ in rats to make the model of type 2 diabetes. Rats in every administration group were given respective drug (50, 100, and 200 mg/kg), and set the model, normal control, and positive control (metformin hydrochloride 0.2 g/kg) groups. After 10 weeks, using glucose oxidase to measure blood glucose of rats in each group; Radioimmunoassay was used to measure INS and get ISI. Measuring the contents of TG, HDL-C, LDL-C, SOD, AR, IL-6, TNF-α, and MDA was detected by TBA. Results: Compared with diabetic model group, kaempferol administration can reduce blood glucose and insulin resistance, restore normal blood lipid levels, along with reducing MDA, AR, TNF-α, and IL-6 levels and increasing SOD levels. Conclusion: Kaempferol can prevent and treat the chronic complications of type 2 diabetic rats by reducing blood glucose, insulin resistance, reducing the AR pathway as well as anti-oxidation and anti-inflammation.